Histocompatibility

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024
Tandem, AML, Neoplasm, FDA, Quality of life, Food, Data, AACR, Histocompatibility, Society, MDS, Transplant, Therapy, Food and Drug Administration, Patient, Clinical trial, TCR, IND, KOL, MAGE-A1, Cancer, Pharmaceutical industry

The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.

Key Points: 
  • The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
  • With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development.
  • Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months.
  • The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Retrieved on: 
Tuesday, October 17, 2023
Science, Biotechnology, Research, Surgery, Health, Health Technology, Genetics, Clinical Trials, Standard of care, Abstract, Paris Institute of Statistics, Society, Laboratory for Experimental Medicine and Surgery in Primates, Parameter, University of Utah, NGS, Assistant, HLA, LIMS, Standard, Caregiver, University, Histocompatibility, Laboratory information management system, St Paul's Cathedral, Chimera, Doctor of Philosophy, ACHI, Kidney transplantation, Biomarker, Laboratory, Patient, Management, Dentistry, Transplant, Nephrology, MD, Immunogenetics, Medicine

These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.

Key Points: 
  • These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.
  • The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies.
  • Ahmed Mostafa, MD, PhD, Director, Technical Supervisor, and Clinical Consultant, Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital—Saskatoon.
  • Virtual Crossmatching and Epitope Analysis as Informational Aids in the Transplant Decision Making Process: A Review of VXMatch and VECTR.

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting

Retrieved on: 
Tuesday, May 2, 2023
TIP, Gene, Histocompatibility, Cancer, Los Angeles Convention Center, American Society of Gene and Cell Therapy, TCR, Patient, Annual general meeting, Cell, Therapy, Society, Vaccine

Following the meeting, TScan will host a virtual event on Wednesday, May 17, 2023, at 5:30 p.m.

Key Points: 
  • Following the meeting, TScan will host a virtual event on Wednesday, May 17, 2023, at 5:30 p.m.
  • Poster Board and Abstract Number: 798
    TScan will host a webcast Wednesday, May 17, 2023, at 5:30 p.m.
  • The event will provide a summary of the ASGCT TIP poster as well as an update on TScan’s Phase 1 umbrella trial.
  • For those unable to participate in the live webcast, a replay will be available following conclusion of the event.

Adagene Announces Updates to its Board of Directors

Retrieved on: 
Friday, April 28, 2023
Yale University, BS, Nature, University, Biochemistry, Doctor of Philosophy, Research, Histocompatibility, Hongkong Electric Company, Biotechnology, California Institute for Telecommunications and Information Technology, Physiology, DRS, DU, Merck & Co., Investment, H5 (US company), Biophysics, Annual report, SAN, Peking University, Drug discovery, Biology, Growth, Merck, Entrepreneurship, General Atlantic, The Hong Kong University of Science and Technology, Washington State University College of Agricultural, Human, and Natural Resource Sciences, Pharmaceutical industry, Management, Science, Illumina, Chemistry

SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following:

Key Points: 
  • SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following:
    Mervyn Turner, Ph.D., is appointed as a director.
  • Dr. Du joined Adagene as Vice President of Technology Development in January 2012 and has served as Chief Technology Officer since May 2019.
  • Adagene appreciates the service of Ms. Liu and her contributions to the Board.
  • I look forward to working with the new directors who bring a breadth of industry experience and new insights to our Board.”

CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference

Retrieved on: 
Tuesday, April 25, 2023
Science, Other Science, Research, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, Experience, Immunogenetics, HLA, Nucleic acid thermodynamics, Histocompatibility, UTR, NGS, Platinum, MicroRNA, Chimera, Ambiguity, Teaching hospital, Regulation, Patient, Necker–Enfants Malades Hospital, National Institute of Allergy and Infectious Diseases, Medicine, Risk assessment, Hospital, Massive parallel sequencing, Phenotype, Conference, Caregiver, Pharmaceutical industry, Dentistry, Medical device, EU

“We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx.

Key Points: 
  • “We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx.
  • For post-transplant, CareDx offers AlloSeq HCT* chimerism testingand AlloSeq cfDNA* for labs to assess transplanted stem cells and organ health, respectively.
  • CareDx also provides pre-transplant HLA typing and post-transplant surveillance testing for customers through its service lab in Stockholm, Sweden, for clinical research.
  • CareDx will sponsor a symposium “Breaking New Ground: Innovative Pre- and Post-Transplant Solutions to Improve Allograft Outcomes” on Thursday, April 27.

Devyser Diagnostics AB: New more sensitive diagnostics protect transplanted kidney

Retrieved on: 
Thursday, March 9, 2023
Transplant, Clinical chemistry, Blood, Dialysis, CKD, Chronic kidney disease, Antibody, DNA, Patient, Kidney transplantation, Risk, Lymphocyte, Medicine, Immune system, Survival, Urine, Immunogenetics, Conference, Creatinine, Acute kidney injury, Kidney, National Academy of Medicine, Histocompatibility, Dentistry, Pharmaceutical industry

With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier, and proper treatment introduced to protect the kidney.

Key Points: 
  • With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier, and proper treatment introduced to protect the kidney.
  • The goal of new more sensitive diagnostics is to increase the survival of the new organ and reduce the need for new transplantation.
  • (1) A major problem associated with kidney transplantation is the risk of damage or kidney loss.
  • The most common causes for this are rejection, surgical complications, or other kidney damage by for instance immunosuppressive drugs.

ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata

Retrieved on: 
Tuesday, February 28, 2023
Yale University, Autoimmune disease, Safety, AA, Hair, MHC, Hair loss, Associate, Patient, R, Scalp, Multiple sclerosis, Research and development, ASLN, Histocompatibility, Immune privilege, DHODH, Alopecia areata, IP, Rheumatoid arthritis, Physician, Vaccine, Pharmaceutical industry, Dermatology

AA is associated with severe psychological burden and has limited treatment options, affecting over 700,000 patients in the US.

Key Points: 
  • AA is associated with severe psychological burden and has limited treatment options, affecting over 700,000 patients in the US.
  • The inhibition of DHODH is an established mechanism for the treatment of several autoimmune diseases.
  • Farudodstat, a highly selective DHODH inhibitor, is 30-fold more potent than approved drugs in its class and has a well-tolerated safety profile.
  • A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical’s website .

Be The Match BioTherapies® Launches Bioinformatics Consulting Services

Retrieved on: 
Wednesday, December 14, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, General Health, Science, MCW, Physician, Genetics, Match, MD, Center for International Blood and Marrow Transplant Research, HCT, HLA, Doctor of Philosophy, Partnership, Histocompatibility, Health, Patient, Science, Genotype, Collection, NMDP, FDA, Medical College of Wisconsin, KIR, Quality of life, Survival, National Marrow Donor Program, Onboarding, Medical college, Dentistry, Pharmaceutical industry, Research

Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services , which blends the unique expertise, real-world data and assets of Be The Match BioTherapies and the CIBMTR (Center for International Blood and Marrow Transplant Research).

Key Points: 
  • Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services , which blends the unique expertise, real-world data and assets of Be The Match BioTherapies and the CIBMTR (Center for International Blood and Marrow Transplant Research).
  • Our Bioinformatics Consulting Services operate at the intersection of science and technology, and bridges the transition from cell culture to the clinic.
  • The new Bioinformatics Consulting Services help companies mitigate risk by using data-driven answers to make decisions that maximize clinical success and speed allogeneic therapies to market.
  • The Bioinformatics Consulting Services experts include Martin Maiers, Vice President, Research; Abeer Madbouly, Principal Bioinformatics Scientist; Michael Wright, Scientific Coordinator; Heather Stefanski, MD, PhD, Vice President, Medical Services; and Steve Devine, MD, Chief Medical Officer.

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
SAN, MHC class I, PFS, Forward-looking statement, Nektar, Merck Group, Histocompatibility, U.S. Securities and Exchange Commission, Patent, Multiple myeloma, Overalls, Squamous cell carcinoma, Annual general meeting, Immunotherapy, Research, Risk, Merck, UC, Colorectal cancer, Development, Population, MHC, COVID-19, Therapy, Heparin, Failure, PD-L1, Limited partnership, Avelumab, Antibody, Safety, PD-1, Infection, Survival, SITC, Senior, Immunology, Neoplasm, Program, PEG, Clinical trial, Maintenance, Cell, B-cell lymphoma, Society for Immunotherapy of Cancer, NK, Nektar Therapeutics, Patient, Treatment, Memory, NKTR, Pfizer, Security (finance), Trial, PD, Trial of the century, Palladium, Pharmaceutical industry, Vaccine, Cancer

SAN FRANCISCO, Nov. 10, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • NKTR-288 is a novel polyethylene glycol (PEG)-conjugate of interferon gamma (IFN-), designed to modify binding of IFN- to its substrates and optimize the duration of IFN- signaling.
  • These data support further evaluation of NKTR-288 as a monotherapy or in combination with checkpoint inhibitors in the clinical setting.
  • It highlights the potential of NKTR-288 to augment currently available PD-1 or PD-L1 treatment strategies and possibly broaden the responsive patient population."
  • Key details and takeaways from the presentation are as follows:
    Abstract 1086: "NKTR-288, a PEGylated Interferon Gamma Drug Candidate for the Treatment of Cancer", Hamel, D., et al.

CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Retrieved on: 
Tuesday, October 25, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical Trials, Diamond, Caregiver, Doctor of Philosophy, SEC, ABB, Annual report, Society, Patient, Transplant, Nasdaq, Time, Precision medicine, Histocompatibility, The Meeting, NGS, Genetic distance, CEO, 2021 Essex County Council election, Hematopoietic stem cell transplantation, ACHI, Solution, HLA, Pharmaceutical industry, Immunogenetics, Research

CareDx is proud to be a leading sponsor of this years ASHI meeting to help drive continued innovation in transplantation through our laboratory products, said Reg Seeto, CEO and President of CareDx.

Key Points: 
  • CareDx is proud to be a leading sponsor of this years ASHI meeting to help drive continued innovation in transplantation through our laboratory products, said Reg Seeto, CEO and President of CareDx.
  • Moderated by Curtis Lind, Vice President and Head of Research and Development Products at CareDx, the symposium includes the following:
    NGS-HLA for Solid Organ Transplant: The Time is Now.
  • Cathi Murphey Half, Ph.D., HCLD/CC(ABB), A(ACHI), Director, Histocompatibility and Immunogenetics Laboratory Southwest Immunodiagnostics, Inc.
  • Eight scientific abstracts highlight the use of CareDxs flagship AlloSeq Tx171, which offers laboratory professionals a novel method for matching transplant recipients and potential donors.